Lipella Pharmaceuticals Inc. Announces Board and Executive Changes
Ticker: LIPO · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Lipella Pharma adds new director Cohen, inks new CEO Diamond deal.
AI Summary
Lipella Pharmaceuticals Inc. announced on October 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected Dr. Jonathan L. Cohen as a new director and appointed him to the Compensation Committee. Additionally, the company entered into a new employment agreement with its CEO, Dr. Robert L. Diamond, effective October 3, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategic direction and operational execution.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- Dr. Jonathan L. Cohen (person) — Newly elected director and Compensation Committee member
- Dr. Robert L. Diamond (person) — CEO with new employment agreement
- October 3, 2025 (date) — Effective date of changes
FAQ
Who was appointed to the Compensation Committee?
Dr. Jonathan L. Cohen was appointed to the Compensation Committee.
What is the effective date of the reported changes?
The earliest event reported is dated October 3, 2025.
What is the company's state of incorporation?
Lipella Pharmaceuticals Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number?
The IRS Employer Identification Number is 20-2388040.
What is the principal executive office address?
The principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
Filing Stats: 403 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2025-10-09 17:00:49
Filing Documents
- g084974_8k.htm (8-K) — 34KB
- 0001753926-25-001602.txt ( ) — 192KB
- lipo-20251003.xsd (EX-101.SCH) — 3KB
- lipo-20251003_lab.xml (EX-101.LAB) — 33KB
- lipo-20251003_pre.xml (EX-101.PRE) — 22KB
- g084974_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 9, 2025 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer